Invitae - News & Events - Press releases

November 8, 2021 Invitae Reports $114.4 Million in Revenue Driven by 296,000 in Billable Volume in Third Quarter of 2021

- Q3 2021 revenue increases more than 66% on volume growth of 89% from Q3 2020 -
- Full-year 2021 revenue expected to grow 60-70%, or between $450-$475 million -
- Hosting conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time - Invitae (NYSE: NVTA) , a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2021. "Year-over-year growth continued at a fast pace in the third quarter as volumes remained strong across the platform," said Sean George, Ph.D., co-founder and CEO of Invitae. "In particular, progress in the oncology group is reflected in current volumes and preparations for high-value, high-margin product introductions over the coming year, supported by multiple ongoing studies. We saw continued progress in our data and platform services, underscored by the integration of Medneon and the Ciitizen technology platform that bolster our ability to collect,

November 8, 2021 Northwestern University and Invitae Present New Research Highlighting the Importance of Genetic Testing for Cardiovascular Conditions at the American Heart Association Scientific Sessions

- Data show benefits of multi-condition gene panels to identify and inform treatment of heritable cardiomyopathies and arrhythmias - Investigators from Northwestern University Feinberg School of Medicine and Invitae (NYSE: NVTA), a medical genetics company, will present the results of a collaborative study on genetic testing for heritable cardiomyopathies and arrhythmias at the American Heart Association (AHA) Scientific Sessions on Saturday, Nov. 13. The study found combined genetic testing for heritable cardiomyopathies and arrhythmias identified clinically relevant variants for one in five patients suspected of having one of these conditions. Two-thirds of the positive findings were projected to have clinical management implications, and more than 10% of patients would have been missed with narrower panels specific to either cardiomyopathy or arrhythmia. "Genetic testing for heritable cardiomyopathy and arrhythmia is recommended by cardiology professional societies, and this study

October 26, 2021 Invitae to Announce Third Quarter 2021 Financial Results on Monday, November 8, 2021

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2021 financial results on Monday, November 8, 2021, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To access the conference call, please register at the link below:
https://conferencingportals.com/event/DqFqYhVe Upon registering, each participant will be provided with call details and a conference ID. Reminders will also be sent to registered participants via email. The live webcast of the call and slide deck, may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website. Following prepared remarks, management will respond to questions from analysts, subject to

October 22, 2021 Invitae, UCL and the Francis Crick Institute Announce New Data From TRACERx Research Collaboration at the 2021 International Society of Liquid Biopsy Congress

- Study uses Invitae Personalized Cancer Monitoring (PCM™) liquid biopsy to accurately profile tumors and enhance cancer circulating tumor DNA-based minimal residual disease (MRD) lead times; highlights promise for personalized cancer care - Invitae (NYSE: NVTA), University College London (UCL), and the Francis Crick Institute today announced new data from their TRACERx lung cancer research collaboration funded by Cancer Research UK and sponsored by UCL. The data, presented by Professor Charles Swanton of UCL and the Francis Crick Institute at the International Society of Liquid Biopsy (ISLB) Congress, further validate the value of liquid biopsy as a less invasive and more comprehensive approach to guiding personalized cancer treatment in the absence of detectable disease by clinical imaging. Previously reported findings from the TRACERx cohort found that monitoring for cancer circulating tumor DNA (ctDNA) based minimal residual disease (MRD) detected relapse of non-small cell lung

September 25, 2021 New Study Highlights the Value of Genetic Testing to Guide Clinical Management and Improve Outcomes for Epilepsy Patients

- Study finds improved seizure control and positive outcomes in 75 percent of patients with actionable genetic findings that led to clinical management changes -
- Data presented at the National Society of Genetic Counselors Annual Conference, which also included a ceremony honoring excellence in genetic counseling patient care - Invitae (NYSE: NVTA), a leading medical genetics company, today presented research demonstrating that genetic findings informed clinical management changes that led to improved seizure control and outcomes in the majority of epilepsy patients with actionable findings. This study underscores the importance of genetic testing for all people with epilepsy and supports the growing evidence that medical genetic testing can improve health outcomes and reduce healthcare costs. The findings were presented at the National Society of Genetic Counselors 40th Annual Conference. "Epilepsy impacts the lives of approximately 50 million people worldwide and our

September 7, 2021 Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research

- Ciitizen platform will empower patients to securely collect, organize and benefit from their full range of health data -
- Combination to bring together the power of genomic and clinical information within a new kind of patient data platform to improve healthcare decision making at personal and systemwide levels -
- Hosting Conference Call and Webcast today at 8:30 a.m. ET / 5:30 a.m. PT - Invitae (NYSE: NVTA) , a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, which together comprise a powerful dataset with the potential to drive research and

September 1, 2021 Invitae to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in a virtual fireside chat at the Morgan Stanley 19 th Annual Global Healthcare Conference on Tuesday, September 14, 2021, at 12:30pm Eastern Time. The live webcast of the virtual fireside chat may be accessed by visiting the investors section of the company website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the virtual fireside chat. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com . Contact:
ir@invitae.com
(628)

August 9, 2021 Invitae to Present at the UBS Genomics 2.0 and MedTech Innovations Summit

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in a fireside chat at the UBS Genomics 2.0 and MedTech Innovations Summit on Wednesday, August 11, 2021 at 11:00 a.m. PT and Sean George, chief executive officer of Invitae, will participate in the NGS Technologies panel presentation at 1:00 p.m. PT, both at Montage Laguna Beach. The live webcasts of the fireside chat and the panel presentation may be accessed by visiting the investors section of the company website at ir.invitae.com . Replays of the webcasts will be available shortly after the conclusion of the fireside chat and panel presentation. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with

August 3, 2021 Invitae Reports $116.3 Million in Revenue Driven by 287,000 in Billable Volume in Second Quarter of 2021

- Increased quarterly revenue by 152% year-over-year -
- Increases guidance of revenue between $475-$500 million in 2021 -
- Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced preliminary financial and operating results for the second quarter ended June 30, 2021 and increases 2021 guide to revenue between $475-$500 million for the year. "Having now served more than 2 million patients, a major milestone for the quarter, we are seeing a clear and steady rise in the rate of adoption of genetics for personalized medicine, and we are sitting at the forefront of making the vision of genetics in mainstream medicine a reality," said Sean George, co-founder and chief executive officer of Invitae. "Years of investment in that reality have delivered yet another strong quarter of growth, and with increased confidence in continuing momentum we are increasing our

July 20, 2021 Invitae to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2021 financial results on Tuesday, August 3, 2021 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To access the conference call and webcast, please register at the link below: http://www.directeventreg.com/registration/event/2732845 Upon registering, each participant will be provided with call details and a registrant ID. Reminders will also be sent to registered participants via email. The live webcast of the call and slide deck, may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website. Following prepared remarks, management will respond to questions from analysts,

June 11, 2021 Invitae appoints technology and medtech veteran Roxi Wen as chief financial officer

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Roxi Wen as its chief financial officer, effective June 21, 2021. Wen brings decades of success as a senior financial executive where she scaled global technology and medical technology companies. "We're delighted Roxi will be joining our team. Her track record of driving growth, financial management and execution of unique business models in the U.S. and international markets across technology and life science settings is well suited to our goals," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. "In addition to her expertise, Roxi shares our team's passion to deliver genetic information improving healthcare for patients worldwide." Wen comes to Invitae from Mozilla Corporation, where she served as CFO for the past two years, leading a transformation covering all aspects of the business, driving capital allocation, building analytics capability, restoring

June 3, 2021 Invitae opens early access to liquid biopsy-based Personalized Cancer Monitoring as a central laboratory service

- Provides monitoring for recurrence of cancer based on each person's tumor-specific genetic information - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has begun offering early access to its new Personalized Cancer Monitoring (PCM™) platform as a laboratory-developed test performed at an Invitae central laboratory. The service employs a novel combination of a tumor profile, blood tests and personalized assays based on a patient's tumor with the goal of detecting circulating tumor DNA (ctDNA) before it is detectable by imaging or other conventional methods, offering earlier detection of cancer recurrence. "Far too many patients who undergo treatment for cancer still relapse, and the cause is often the development of new cancer cell populations. One promising strategy for identifying recurrence early is to detect these cancer cells persisting in a patient after treatment, known as minimal residual disease (MRD), that cannot be detected with

May 25, 2021 Germline genetic testing can benefit all cancer patients as a routine practice in cancer care

- New data to be presented at 2021 ASCO Annual Meeting highlight need for increased germline testing in all cancer patients regardless of medical policy - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, is presenting multiple studies in multiple cancer types at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting showing all cancer patients can benefit from germline genetic testing to guide their care. The use of genetic information informs changes in cancer care, increases access to precision therapies and guides screening for high-risk individuals and their family members. Earlier detection and precision therapies are critical to increase survivorship for people with cancer, yet the oncology community has been slow to adopt routine testing. "Cancer is a disease of genetics, yet clinical practice has struggled to keep pace with rapid advancements in research, particularly with respect to the role of germline genetics. Testing guidelines and

May 20, 2021 Invitae to Present at the William Blair 41st Annual Growth Stock Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the William Blair 41st Annual Growth Stock Conference on Thursday, June 3, 2021 at 3:20 p.m. Central / 4:20 p.m. Eastern / 1:20 p.m. Pacific. The live webcast of the fireside chat may be accessed by visiting the investors section of the company website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the fireside chat. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com . Contact:
Laura D'Angelo
ir@invitae.com
(628)

May 4, 2021 Invitae Reports $103.6 Million in Revenue Driven by 259,000 in Billable Volume in First Quarter of 2021

- Increased quarterly revenue by 61% and volume by 72% year-over-year -
- Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2021 signaling continued momentum into 2021. "We had a very strong start to the year, experiencing record daily volumes, and we expect that momentum to continue into the coming years," said Sean George, co-founder and chief executive officer of Invitae. "Genetic information is the foundation for personalized medicine, and we believe Invitae is uniquely positioned to deliver that information from a single platform across all stages of life, ushering personalized medicine into the mainstream to improve healthcare for all." First Quarter 2021 Financial Results Generated revenue of $103.6 million in the quarter, a 61% increase compared to $64.2 million in the same period in 2020

April 20, 2021 Invitae to Open New Facility in North Carolina to Support Continued Growth

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced its plans to open a new laboratory and production facility in North Carolina to further expand its capacity to meet the growing demand for genetic testing services globally. "As we continue to expand to support our rapid growth worldwide, we were eager to identify a location on the East Coast that would improve our ability to serve our customers, improve our operational leverage, and build a talented team with connections to a vibrant life sciences community. We have found the ideal location in North Carolina," said Ken Knight, chief operating officer of Invitae. "Our mission is to make genetic information affordable and accessible for billions of people. Our new location near the Research Triangle Park will help us bring that mission to reality." "Biotechnology companies continue to choose North Carolina as a trusted and reliable location to grow their companies," said Governor Ray Cooper. "From

April 20, 2021 Invitae to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To access the conference call and webcast, please register at the link below:
http://www.directeventreg.com/registration/event/6480598 Upon registering, each participant will be provided with call details and a registrant ID. Reminders will also be sent to registered participants via email. The live webcast of the call and slide deck, may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website. Following prepared remarks, management will respond to questions from analysts,

April 15, 2021 Study finds risk-causing genetic changes in nearly 1 in 6 patients with colorectal cancer

- Cancer-linked genetic changes associated with younger age at diagnosis - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced research showing one in six people with colorectal cancer harbor genetic changes that are known to substantially increase the risk for cancer, especially in patients who were younger when diagnosed. The findings are the latest from a landmark study of genetic testing across many solid tumor cancers and were presented at the 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. "Colorectal cancer is one of the most common types of cancer. Recently we've seen an unfortunate increase in incidence among people younger than 50 years old. Improving our understanding of who is at risk and implementing appropriate screening strategies is essential to ensuring these cancers are caught and treated earlier when outcomes are typically better," said Robert Nussbaum, M.D., chief medical officer of

April 8, 2021 Invitae joins NIH-sponsored study aimed at improving understanding of the links between genes and cancer, heart disease and other conditions

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, has joined eMERGE Network, a nationwide effort organized and funded by the National Human Genome Research Institute (NHGRI) that connects genetic data and electronic medical record (EMR) systems to advance the use of genetics in healthcare. As a new clinical affiliate, Invitae will provide genetic testing for a study of up to 25,000 patients to evaluate the impact of population screening. "Our own research has shown that people can harbor a genetic change that could put them at increased risk for conditions like cancer and heart disease. The eMERGE study is part of the work conducted by the NHGRI to improve understanding of these rates in diverse populations, with an emphasis on underrepresented minorities, and identify best practices for population screening," said Robert Nussbaum, M.D., chief medical officer at Invitae. "We're proud to be participating in this important effort, through which we hope to not only

April 5, 2021 Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives

Invitae (NYSE: NVTA), a leading medical genetics company, today announced that a small group of investors, led by SB Management, a subsidiary of Softbank Group Corp., will make an investment of $1.15 billion in convertible senior notes to support the Company's future growth initiatives. "Invitae's mission is to deliver genetic information to improve healthcare for billions of people at all stages of life. With the support of our long-term shareholders, we're creating the platform to support the routine use of genetics in mainstream medicine to result in better healthcare for everyone," said Sean George, co-founder and chief executive officer of Invitae. "This investment will help us continue to fuel our growth, including expanding our platform, services and menu through both in-house development and the addition of complementary companies and technologies as we work to build a differentiated platform uniquely capable of driving the transition to personalized medicine." "Invitae has a

April 5, 2021 Invitae to acquire Genosity to accelerate access to personalized oncology testing worldwide

Acquisition to support the speed, efficiency and flexibility needed for mainstream global adoption of personalized cancer care and monitoring Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Genosity Inc. ("Genosity"), a genomics company offering innovative software and laboratory solutions to enable development and deployment of complex sequencing based tests. The acquisition would bring Genosity's specialized capabilities onto the Invitae platform to accelerate the time to market and decentralization of Invitae's personalized oncology offerings, including somatic and germline offerings poised to help transform how cancer is diagnosed, treated and monitored. "Each individual cancer is unique. The way we diagnose and treat it must be as well," said Robert Nussbaum, M.D., chief medical officer of Invitae. "Our goal is to move as quickly as we can toward the day where each cancer patient receives timely,

April 1, 2021 Invitae introduces new program to increase access to genetic testing for adult neurodegenerative conditions

- New sponsored testing program can make it easier for patients to receive genetic testing in Parkinson's disease, early-onset Alzheimer's disease, ALS and other common conditions - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the availability of sponsored genetic testing for patients in the U.S., Canada, Australia and Brazil who are suspected of having or are at risk for developing some of the most common adult neurodegenerative conditions, including Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and early-onset Alzheimer's disease (AD). The new program will make genetic testing available at no charge to individuals at risk for or suspected of having these difficult-to-diagnose conditions. Sponsored testing programs have been shown to increase access to genetic testing, which can help confirm a diagnosis, inform treatment and enable participation in clinical trials for patients. "As a researcher and clinician working to provide

March 11, 2021 Invitae Releases Inaugural Environmental, Social and Governance (ESG) Report

- Benchmark report marks beginning of increased focus on sustainability issues, in recognition of their impact on its business and patient health - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the issuance of its inaugural Environmental, Social and Governance (ESG) report, augmenting the company's disclosures regarding its ESG strategy and capabilities. "Those of us who have dedicated our careers to improving healthcare understand deeply the impacts of climate change and the environment, social inequity and the actions of corporations on the health of individuals. At Invitae, our mission is to improve healthcare for billions of individuals, making our ability to incorporate key ESG factors into our strategy core to our future," said Shelly Guyer, chief financial officer and leader of the company's sustainability initiatives. "I couldn't be more proud to now spearhead Invitae's efforts in the important areas of ESG. Sustainability has been a

March 4, 2021 Invitae to Present at the Oppenheimer 31st Annual Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021 at 10:40 a.m. Eastern / 7:40 a.m. Pacific. The live webcast of the fireside chat may be accessed by visiting the investors section of the company website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the fireside chat. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com . Contact:
Laura D'Angelo
ir@invitae.com
(628) 213-3369 View original

February 24, 2021 Invitae adds Medneon's risk assessment tools to its education and clinical support offerings

- Easy-to-use software makes it easier for clinicians to use genetics to improve patient care - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the addition of tools from Medneon, a digital health AI company, to its robust clinical workflow and patient education tools. The additional capabilities further support clinicians and patients with cancer by making it easier to determine who should get testing and how to use genetic information to individualize treatment. "While utility of genetic information in cancer care is well established, it remains challenging for clinicians to navigate varying guidelines and research findings that inform them about which patient, which test and what results mean for patient care," said Robert Nussbaum, M.D., chief medical officer at Invitae. "The addition of Medneon's risk assessment tool, which was developed by experts in the field, makes it easier for clinicians to make sure testing is considered and findings

February 23, 2021 Invitae expands capabilities of its advanced clinical chatbot Gia, enhancing telemedicine support for patients and clinicians

- Clinicians can now share test results reports with patients directly, reducing delays and need for in-person visits - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced expanded capabilities that enable clinicians to use its advanced clinical chatbot Gia to guide their patients in an intuitive, enjoyable and telemedicine-friendly conversation through receiving and understanding genetic test results and possible next steps, including scheduling a call with a genetics counselor. "While the pandemic brought new urgency to the need for telemedicine-friendly patient tools, we've known for a long time that Gia can make the genetic testing process easier and more accessible for both patients and clinicians," said Moran Snir, co-developer of Gia and head of experience platform at Invitae. "By adding support for returning results to Gia's capabilities, we can help reduce delays caused by wait lists for in-person appointments and hours of travel to

February 22, 2021 Invitae to Present at The Cowen 41st Annual Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at The Cowen 41st Annual Healthcare Conference on Tuesday, March 2, 2021 at 2:50 p.m. Eastern /11:50 a.m. Pacific. The live webcast of the fireside chat may be accessed by visiting the investors section of the company website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the fireside chat. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com . Contact:
Laura D'Angelo
ir@invitae.com (628) 213-3369 View original content to download

February 17, 2021 Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020

- Increased annual revenue by 29% and annual billable volume by 41% year-over-year -
- Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2020. "Our results in 2020 demonstrate our ability to deliver sustained growth through commercial execution, a diversified global organization and continuous strategic additions to our menu, services and platform," said Sean George, co-founder and chief executive officer of Invitae. "Even amid the challenges of the pandemic, the durability of our relationships and the value of the information we provide to clinicians and patients was clear. As we enter 2021, we are committed to maintaining the pace we've set, making it ever-easier to integrate genetic information into healthcare decision-making by clinicians and patients at all stages of life."

February 10, 2021 Invitae to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at noon Eastern/9:00 a.m. Pacific. The live webcast of the fireside chat may be accessed by visiting the investors section of the company website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the fireside chat. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com . Contact:
Laura D'Angelo
ir@invitae.com (628) 213-3369 View original content

February 3, 2021 Invitae to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2020 financial results on Wednesday, February 17, 2021 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To register for the conference call and webcast, please use one of the methods below. Upon registering, each participant will be provided with call details and a registrant ID. Reminders will also be sent to registered participants via email. Online registration: http://www.directeventreg.com/registration/event/2952997 Phone registration: 833-508-4355 or 415-481-6010 The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the

January 26, 2021 Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock and Closing of Underwritten Public Offering

Invitae Corporation (NYSE: NVTA) today announced the closing of its underwritten public offering of 8,932,038 shares of its common stock, including 1,165,048 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, at the public offering price of $51.50 per share. As a result of the underwriters' option exercise, the aggregate gross proceeds to Invitae from the offering, before deducting underwriting discounts and commissions and other offering expenses, was approximately $460.0 million. J.P. Morgan Securities LLC, Morgan Stanley, Cowen and Company, LLC and SVB Leerink LLC acted as the book-running managers for the offering. William Blair & Company, L.L.C. acted as co-manager for the offering. An automatic shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and became effective on March 4, 2019. A copy of the final prospectus supplement and accompanying prospectus relating to the

January 21, 2021 Invitae Announces Pricing of Public Offering of Common Stock

Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $400.0 million. The offering is expected to close on or about January 26, 2021, subject to customary closing conditions. In addition, Invitae has granted the underwriters a 30-day option to purchase up to an additional 1,165,048 shares of its common stock at the public offering price, less underwriting discounts and commissions. Invitae currently intends to use the net proceeds from the offering for working capital and other general corporate purposes, including investing in its platform, oncology and reproductive product extensions and international expansion. Invitae may also use a portion of

January 20, 2021 Invitae Announces Proposed Public Offering of Common Stock

Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $60.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Invitae currently intends to use the net proceeds from this offering for working capital and other general corporate purposes, including investing in its platform, oncology and reproductive product extensions and international expansion. Invitae may also use a portion of the net proceeds from this

January 14, 2021 Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)

- Project aims to standardize MRD data generation, assessment and accelerate AML clinical trial programs bringing novel therapies to patients in need faster - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the launch of a new project with Bristol Myers Squibb, Janssen Research & Development, LLC (Janssen), Novartis and Genentech, a member of the Roche Group, to develop a standardized panel for MRD detection in patients with AML to support clinical trial testing across multiple drug development programs. The companies are working together to standardize how MRD data is generated and assessed in clinical trials helping to better establish the clinical utility of MRD as a biomarker in AML. "Given the existing evidence that shows assessing the presence of MRD can provide valuable information on how well a treatment may be working, we hope to further establish MRD detection as an objective tool for clinicians to create the best treatment plan for

January 11, 2021 Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume

- Presenting at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2020 results, reporting strong growth in volume and revenue, signaling continued momentum into 2021. "We are very pleased by the acceleration of our business in 2020, particularly in light of the impact of the COVID-19 pandemic on the healthcare system throughout the year," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. "Our results underscore the strength of our customer relationships, our continued ability to execute and the benefits of the investments we've made in expanding our menu, services and platform. The growth in testing during this time of unrelenting stress on the healthcare system further demonstrates the expanding value genetic information is providing patients as they and their physicians face health

Press releases

FORWARD-LOOKING STATEMENTS

Investor Contact